Literature DB >> 2090519

Differential expression of muscle-specific enolase in embryonic and fetal myogenic cells during mouse development.

G Barbieri1, L De Angelis, S Feo, G Cossu, A Giallongo.   

Abstract

Three isoforms of the glycolytic enzyme enolase are present in mammals and birds. During development, a switch from the alpha to the beta form takes place in skeletal muscle. In order to investigate the molecular basis of this developmental transition of enolase isoforms, we extracted total RNA from limbs of mouse embryos of different ages, and from cultures of embryonic and fetal myogenic cells. The beta message was detected in limbs from 16-day-old fetuses by Northern-blot analysis and its level was found to increase in newborn and adult muscle; no significant amount of beta mRNA was present in samples from earlier developmental stages, which did however express high levels of the muscle-specific actin mRNA. Analysis of RNA extracted from embryonic and fetal myoblasts differentiated in culture revealed that the level of beta mRNA is about 9-fold higher in fetal myotubes than in embryonic myotubes, although the level of muscle actin is comparable in both types of myotubes. These results were confirmed by S1 nuclease protection experiments. Our data show that the appearance of beta enolase transcripts temporally correlates with the formation of the second generation of muscle fibers and suggest that the developmental transition from alpha to beta enolase is linked to a developmental program which takes place in fetal but not in embryonic muscle.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2090519     DOI: 10.1111/j.1432-0436.1990.tb00471.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  8 in total

1.  The beta enolase subunit displays three different patterns of microheterogeneity in human striated muscle.

Authors:  T Merkulova; L E Thornell; G Butler-Browne; C Oberlin; M Lucas; N Lamandé; M Lazar; A Keller
Journal:  J Muscle Res Cell Motil       Date:  1999-01       Impact factor: 2.698

2.  Role of mRNA stability and translation in the expression of cytochrome c oxidase during mouse myoblast differentiation: instability of the mRNA for the liver isoform of subunit VIa.

Authors:  E L Thames; D A Newton; S A Black; L H Bowman
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

Review 3.  Nuclear factor one transcription factors: Divergent functions in developmental versus adult stem cell populations.

Authors:  Lachlan Harris; Laura A Genovesi; Richard M Gronostajski; Brandon J Wainwright; Michael Piper
Journal:  Dev Dyn       Date:  2014-09-11       Impact factor: 3.780

4.  The muscle-specific enolase is an early marker of human myogenesis.

Authors:  F Fougerousse; F Edom-Vovard; T Merkulova; M O Ott; M Durand; G Butler-Browne; A Keller
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

5.  Maturation of the myogenic program is induced by postmitotic expression of insulin-like growth factor I.

Authors:  A Musarò; N Rosenthal
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

6.  Differential expression of neuron-specific enolase mRNA in mouse neuroblastoma cells in response to differentiation inducing agents.

Authors:  V Matranga; D Oliva; S Sciarrino; L D'Amelio; A Giallongo
Journal:  Cell Mol Neurobiol       Date:  1993-04       Impact factor: 5.046

7.  Pax7 as molecular switch regulating early and advanced stages of myogenic mouse ESC differentiation in teratomas.

Authors:  Anita Florkowska; Igor Meszka; Magdalena Zawada; Diana Legutko; Tomasz J Proszynski; Katarzyna Janczyk-Ilach; Wladyslawa Streminska; Maria A Ciemerych; Iwona Grabowska
Journal:  Stem Cell Res Ther       Date:  2020-06-17       Impact factor: 6.832

8.  Transcription of the human beta enolase gene (ENO-3) is regulated by an intronic muscle-specific enhancer that binds myocyte-specific enhancer factor 2 proteins and ubiquitous G-rich-box binding factors.

Authors:  S Feo; V Antona; G Barbieri; R Passantino; L Calì; A Giallongo
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.